Adicet Bio, Inc. (ACET) |
|
1.44 0.01 (0.7%)
|
09-27 16:00 |
|
Open: |
1.44 |
Pre. Close: |
1.43 |
|
High:
|
1.51 |
Low:
|
1.43 |
|
Volume:
|
203,389 |
Market Cap:
|
62(M) |
|
|
|
Technical analysis |
as of: 2023-09-27 4:17:26 PM |
|
Short-term rate:
|
  |
| Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
|
Mid-term rate:
|
 |
| Target: |
Six months: 2.1 One year: 2.41 |
| Support: |
Support1: 1.37 Support2: 1.13 |
| Resistance: |
Resistance1: 1.8 Resistance2: 2.06 |
| Pivot: |
1.61  |
| Moving Average: |
MA(5): 1.45 MA(20): 1.68
MA(100): 3.43 MA(250): 7.89 |
| MACD: |
MACD(12,26): -0.2 Signal(9): -0.2 |
| Stochastic oscillator: |
%K(14,3): 9.2 %D(3): 5 |
| RSI: |
RSI(14): 31.9 |
| 52-week: |
High: 21.87 Low: 1.37 |
| Average Vol(K): |
3-Month: 590 (K) 10-Days: 329 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ACET ] has closed above bottom band by 15.8%. Bollinger Bands are 65.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 35 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
1.55 - 1.56 |
1.56 - 1.57 |
|
Low:
|
1.35 - 1.36 |
1.36 - 1.37 |
|
Close:
|
1.41 - 1.43 |
1.43 - 1.45 |
|
Company Description |
|
Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors. Adicet Bio, Inc. is based in Boston, Massachusetts. |
Headline News |
Wed, 27 Sep 2023
Adicet Bio to Present Three Scientific Posters Highlighting its ... - Business Wire
Wed, 06 Sep 2023
Analyst Expresses Positive Outlook on Adicet Bio with 27 Price Target - Best Stocks
Thu, 31 Aug 2023
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule ... - Business Wire
Wed, 09 Aug 2023
Adicet Reports Second Quarter 2023 Financial Results and Provides Business Updates - Yahoo Finance
Tue, 11 Jul 2023
Adicet Announces Appointment of Katie Peng to the Board of Directors - Yahoo Finance
Tue, 27 Jun 2023
Adicet Bio Inc (ACET) Stock Falls -28.24% This Week: Is It a Good Pick? - InvestorsObserver
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
43 (M) |
| Shares Float |
27 (M) |
|
% Held by Insiders
|
3.3 (%) |
|
% Held by Institutions
|
96 (%) |
|
Shares Short
|
2,700 (K) |
|
Shares Short P.Month
|
2,300 (K) |
Stock Financials |
|
EPS
|
-2.6 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
5.55 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-25.3 |
|
Return on Equity (ttm)
|
-43.3 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0.58 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-2.75 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-83 (M) |
|
Levered Free Cash Flow
|
-67 (M) |
Stock Valuations |
|
PE Ratio
|
-0.56 |
|
PEG Ratio
|
-0.1 |
|
Price to Book value
|
0.25 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-0.75 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
